ResMed (RMD) Stock Forecast & Price Target

$222.95 +3.25 (+1.48%)

Closing price 03/24/2025 03:59 PM Eastern

Extended Trading

$222.07 -0.88 (-0.40%)

As of 03/24/2025 07:31 PM Eastern

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
1

Hold
5

Buy
10

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 5 have given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$246.83
10.71% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $246.83. The highest price target for RMD is $286.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted upside of 10.71% from the current price of $222.95.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	7 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$246.83	$244.73	$227.91	$196.30
Forecasted Upside	10.71% Upside	5.66% Upside	-2.01% Downside	1.55% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy

Remove Ads

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.71% Upside	21,090.58% Upside	16.93% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/19/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Overweight	$280.00	+27.23%
3/5/2025	Citigroup 3 of 5 stars	Mathieu Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
3/5/2025	Stifel Nicolaus 4 of 5 stars	Jonathan Block Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$250.00 ➝ $240.00	+8.46%
1/31/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sutcliffe Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
1/31/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$270.00 ➝ $286.00	+17.10%
1/31/2025	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brett Fishbin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$266.00 ➝ $280.00	+15.29%
1/31/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$252.00 ➝ $260.00	+7.89%
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
1/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Thillainathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
10/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$224.00 ➝ $232.00	-9.68%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:19 AM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, March 21, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. has received multiple upgrades from analysts, including a recent upgrade to a "buy" rating by Citigroup, indicating strong confidence in the company's future performance.
The stock is currently priced at approximately $246.83, which is close to its consensus target price, suggesting potential for growth as it approaches or exceeds this target.
ResMed Inc. reported a strong quarterly earnings performance, with earnings per share of $2.43, surpassing estimates and reflecting solid financial health.
The company has a low debt-to-equity ratio of 0.13, indicating a strong balance sheet and lower financial risk, which is attractive to investors looking for stability.
ResMed Inc. has a robust dividend yield of 0.96%, providing investors with a steady income stream, which is particularly appealing in uncertain market conditions.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Despite positive ratings, one analyst has issued a sell rating, indicating that there are differing opinions on the stock's future performance.
The stock has experienced fluctuations, with a fifty-two week low of $172.19, suggesting potential volatility that could deter risk-averse investors.
Insider selling has been noted, with significant shares sold recently, which may raise concerns about the confidence of company executives in the stock's future performance.
The current price-to-earnings ratio of 26.11 may indicate that the stock is overvalued compared to its earnings, which could be a red flag for value investors.
Analysts expect earnings per share to be 9.47 for the current fiscal year, which may not meet the growth expectations of some investors, leading to potential disappointment.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $246.83, with a high forecast of $286.00 and a low forecast of $180.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 5 hold ratings, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted upside of 10.71% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 2 upgrades by analysts.
: ResMed has been rated by research analysts at Citigroup, JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.69 while the average consensus rating score for "medical" companies is 2.82. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:RMD) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target